How to Start Trimi: Your Complete Guide to Beginning GLP-1 Treatment
Starting GLP-1 weight loss treatment should be straightforward, not stressful. Here is exactly what happens from the moment you visit trytrimi.com to receiving your first medication delivery.
You have researched GLP-1 medications. You understand the benefits of semaglutide and tirzepatide. You are ready to start. The only question left is how. Trimi has designed the onboarding process to be as simple and fast as possible while maintaining the medical rigor that your health deserves.
Medical Disclaimer
GLP-1 medications require a prescription. Not everyone is a candidate. Your Trimi medical provider will determine if treatment is appropriate for your individual situation.
The Step-by-Step Process
Complete Your Health Profile (5 minutes)
Visit trytrimi.com and answer questions about your medical history, current medications, health conditions, height, weight, and goals. This information helps our medical team evaluate whether GLP-1 treatment is right for you.
Choose Your Medication
Select from three GLP-1 options: compounded semaglutide ($99/mo), compounded tirzepatide ($125/mo), or retatrutide. Not sure which is right? Your provider will help you decide during your evaluation.
Medical Evaluation (24-48 hours)
A licensed Trimi medical provider reviews your health profile, checks for contraindications, and determines if treatment is appropriate. They may follow up with additional questions or request lab work.
Prescription and Pharmacy Processing
Once approved, your provider sends your prescription to one of Trimi's licensed compounding pharmacy partners. The pharmacy compounds your medication and prepares it for shipment.
Temperature-Controlled Shipping
Your medication ships in temperature-controlled packaging to ensure potency. Tracking information is provided so you know exactly when to expect delivery.
Start Treatment
Your shipment includes your medication, supplies, and dosing instructions. Begin with your starting dose and follow the titration schedule your provider outlines. Your Trimi team is available for questions anytime.
What to Expect in Your First Month
First Month Timeline
- Week 1: Start at the lowest dose. Some appetite reduction begins. Mild GI side effects are common.
- Week 2: Appetite suppression becomes more noticeable. Eat protein-first at meals.
- Week 3-4: Weight loss typically begins. Side effects usually improve. Focus on hydration and protein.
- End of Month 1: Most patients lose 3-7 pounds. Your provider will evaluate whether a dose increase is appropriate.
Who Qualifies for Trimi
Trimi treats adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea. You must be 18 or older and not have contraindications including personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, or active pancreatitis.
Switching from Another Provider
If you are already taking a GLP-1 medication from another provider, switching to Trimi is seamless. Share your current medication and dose during your health profile. Your Trimi provider can continue your treatment at your current dose without restarting the titration process. Many patients switch to take advantage of Trimi's lower pricing and broader medication options.
Ready to Start?
The hardest part of any weight loss journey is starting. Trimi makes it as easy as completing a five-minute health profile from your phone or computer. No waiting rooms. No insurance battles. No contracts. Just effective medical treatment at a price that makes sense.
Start Your Trimi Journey Today
Semaglutide $99/mo. Tirzepatide $125/mo. Retatrutide available. No contracts, no hidden fees.
Get Started NowMore on trimi
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).